Century Therapeutics, Inc. (IPSC) vs Palisade Bio, Inc. (PALI)

Century Therapeutics, Inc. and Palisade Bio, Inc. are both Biotechnology companies. Century Therapeutics, Inc. and Palisade Bio, Inc. are of similar size ($271.6M and $268.4M). Century Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Century Therapeutics, Inc. grew revenue faster over the last twelve months: 8,286.7% against 5,492.6%. Century Therapeutics, Inc. has the higher net margin (0.00% vs −4,230.6%) and the lower return on invested capital (−64.9% vs 0.00%). Across the 16 metrics below, Century Therapeutics, Inc. leads on 10 and Palisade Bio, Inc. on 6.

Valuation

Metric IPSC PALI Biotechnology median
P/E n/m 2.18 8.50
P/S 2.45 394.77 9.71
P/B 1.21 2.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.41 229.61 9.21
Earnings yield (67.88%) 45.93% (33.15%)
Free cash flow yield (31.23%) (6.11%) (25.50%)

Profitability

Metric IPSC PALI Biotechnology median
Gross margin 100.00% 95.63% 65.16%
Operating margin 0.00% (4,681.99%) 0.00%
Net margin 0.00% (4,230.60%) 0.00%
Free cash flow margin 0.00% (2,409.27%) 0.00%
Return on equity (49.65%) (51.37%) (56.36%)
Return on assets (38.41%) (47.68%) (48.04%)
Return on invested capital (64.92%) 0.00% 0.00%

Growth

Metric IPSC PALI Biotechnology median
Revenue growth (TTM) 8,286.72% 5,492.59% 6.02%
EPS growth (last fiscal year) 93.12% 97.06% 30.26%
Revenue growth, 5-year CAGR — 72.86% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IPSC PALI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.28 24.26 4.72
Net debt to EBITDA 17.95 7.37 0.96

Dividend

Metric IPSC PALI Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IPSC PALI Biotechnology median
Market cap 271.61m 268.38m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack